|
WO2021056048A1
|
|
Therapeutic formulations and uses thereof
|
|
WO2020000065A2
|
|
Substituted-n-heteroaryl compounds and uses thereof
|
|
WO2020077414A1
|
|
Cyclic compounds as receptor modulating therapeutics and methods and uses thereof
|
|
AU2019275493A1
|
|
Substituted-pyridinyl compounds and uses thereof
|
|
AU2019271420A1
|
|
Modulators of ion channel receptors and uses thereof
|
|
AU2019271419A1
|
|
Pain treating compounds and uses thereof
|
|
EP3775913A1
|
|
Method of monitoring response to a treatment
|
|
WO2019126842A1
|
|
Therapeutic compounds and uses thereof
|
|
WO2019109150A1
|
|
Methods of treating agitation
|
|
WO2019109132A1
|
|
Isoxazolyl compounds as receptor modulating compounds and methods and uses thereof
|
|
EP3700632A1
|
|
Method for treating acute myeloid leukemia
|
|
US2018105523A1
|
|
Anxiolytic compounds
|
|
WO2018102885A1
|
|
Modulators of nicotinic acetylcholine receptors and uses thereof
|
|
EP3512548A1
|
|
Antibody and checkpoint inhibitor combination therapy
|
|
US2020114017A1
|
|
Antibody drug conjugates that bind lgr5
|
|
KR20180138205A
|
|
Administration of anti-LGR5 monoclonal antibody
|
|
WO2016197204A1
|
|
Pharmaceutical combination and uses thereof
|
|
EP3265080A1
|
|
Combination treatment protocol
|
|
AU2015264805A1
|
|
Combination Therapy
|
|
AU2015283812A1
|
|
Predictive baseline biomarkers for use of vascular disrupting agents
|
